Study of Coenzyme Q10 Treatment for Veterans with Gulf War Illness to Improve Symptoms and Quality of Life

What this Trial Is About

Researchers are evaluating whether a high-quality preparation of ubiquinone coenzyme Q10 can improve symptoms, function, and quality of life in veterans with Gulf War illness. This Phase 3 study focuses on veterans who meet specific deployment and symptom criteria and aims to replicate previous findings related to coenzyme Q10s potential effects in this population. Participants are randomly assigned to one of three groups one group receives 100 mg of PharmaNord Bio-Quinone Active CoQ10 Gold once daily with placebo softgels to match dosing a second group receives 100 mg three times daily and the third group receives placebo softgels three times daily. The supplement is taken orally in divided doses, with the last dose not close to bedtime. Treatment lasts for 3.5 months. During the study, participants will complete symptom surveys, timed chair rise tests, and general self-rated health assessments. Blood samples will be collected to measure coenzyme Q10 levels. Researchers will monitor changes in symptoms and physical function at 3.5 and 7 months. The study includes remote visits via Zoom and requires participants to have adequate internet access. The total participation duration includes treatment and follow-up assessments, with safety and adherence monitored throughout.

Coenzyme Q10 for Gulf War Illness: A Replication Study